These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26638045)

  • 1. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
    Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
    Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors.
    Adekoya OA; Sjøli S; Wuxiuer Y; Bilto I; Marques SM; Santos MA; Nuti E; Cercignani G; Rossello A; Winberg JO; Sylte I
    Eur J Med Chem; 2015 Jan; 89():340-8. PubMed ID: 25462250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
    Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
    PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
    Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
    Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of bacterial and human zinc-metalloproteases by bisphosphonate- and catechol-containing compounds.
    Rahman F; Nguyen TM; Adekoya OA; Campestre C; Tortorella P; Sylte I; Winberg JO
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):819-830. PubMed ID: 33757387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations.
    Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N
    J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
    Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP-2 selectivity in hydroxamate-type inhibitors.
    Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
    Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carborane-Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron-Capture Therapy (BNCT).
    Lutz MR; Flieger S; Colorina A; Wozny J; Hosmane NS; Becker DP
    ChemMedChem; 2020 Oct; 15(20):1897-1908. PubMed ID: 32720425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
    Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors.
    Marcotte PA; Elmore IN; Guan Z; Magoc TJ; Albert DH; Morgand DW; Curtin ML; Garland RB; Guo Y; Heyman HR; Holms JH; Sheppard GS; Steinman DH; Wada CK; Davidsen SK
    J Enzyme Inhib; 1999; 14(6):425-35. PubMed ID: 10536876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
    Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
    J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present.
    Baidya SK; Amin SA; Jha T
    Eur J Med Chem; 2021 Mar; 213():113044. PubMed ID: 33279289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors.
    Bertran A; Khomiak D; Konopka A; Rejmak E; Bulska E; Seco J; Kaczmarek L; Tarragó T; Prades R
    Bioorg Chem; 2020 Jan; 94():103365. PubMed ID: 31676116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.
    Nuti E; Casalini F; Santamaria S; Gabelloni P; Bendinelli S; Da Pozzo E; Costa B; Marinelli L; La Pietra V; Novellino E; Margarida Bernardo M; Fridman R; Da Settimo F; Martini C; Rossello A
    Eur J Med Chem; 2011 Jul; 46(7):2617-29. PubMed ID: 21514700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.